Kathleen Flint, MD
Rheumatology · Columbia, SCNPI 1962490771
Payments from drug & device makers
Across 854 payments — averaging $618.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$240K
- Gilead$98K
- AbbVie$62K
- Eli Lilly$51K
- Janssen Research & Development, LLC$49K
- Amgen$8K
- plus $19K from 28 others
Across 4 payments — averaging $1731.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6K
- Gilead$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 84 | $240,023 |
| Gilead | 36 | $98,161 |
| AbbVie | 102 | $62,089 |
| Eli Lilly | 7 | $51,150 |
| Janssen Research & Development, LLC | 9 | $49,281 |
| Amgen(2 entities) | 160 | $8,009 |
| Pfizer | 85 | $7,705 |
| GSK | 35 | $4,483 |
| UCB, Inc. | 55 | $1,211 |
| AstraZeneca(2 entities) | 39 | $960 |
| Lilly USA, LLC | 53 | $887 |
| E.r. Squibb & Sons, L.L.C. | 37 | $525 |
| Octapharma USA, Inc. | 5 | $503 |
| Boehringer Ingelheim | 19 | $393 |
| Johnson & Johnson | 17 | $348 |
| Mallinckrodt Hospital Products Inc. | 12 | $327 |
| Organon | 12 | $309 |
| Bristol Myers Squibb | 14 | $261 |
| Radius Health, Inc. | 12 | $254 |
| Fresenius Kabi USA, LLC | 9 | $186 |
| Regeneron Healthcare Solutions, Inc. | 12 | $177 |
| Sandoz | 7 | $130 |
| ANI Pharmaceuticals, Inc. | 2 | $85 |
| Medexus Pharma, Inc. | 7 | $82 |
| Almatica Pharma LLC | 5 | $81 |
| Genentech USA, Inc. | 4 | $74 |
| Mallinckrodt Enterprises LLC | 3 | $68 |
| Aurinia Pharma U.S., Inc. | 4 | $68 |
| Antares Pharma, Inc. | 3 | $66 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| Pacira Therapeutics, Inc. | 1 | $22 |
| Merck | 1 | $15 |
| Sebela Pharmaceuticals Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $12 |
How this compares
$527,982 in reported general payments places this provider in the 90th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Columbia
- Sunita PaudyalColumbia$64K
- Suneetha MorthalaColumbia$28K
- Robert BoydColumbia$10K
- Adam MeszarosColumbia$7K
- Clarence LegertonSummerville$7.7M
- Gary FinkSummerville$6.9M
- William EdwardsSummerville$5.9M
- Colin EdgertonSummerville$4.6M
- Gregory NiemerSummerville$4.4M
- Jennifer MurphySummerville$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.